Apatinib is a small molecule tyrosine kinase inhibitor that highly and selectively targets VEGFR‐2 and also inhibits the activities of VEGFR‐1, Kit, c‐SRC and RET,59 leading to the inhibition of endothelial cell migration and proliferation, and decrease in tumour microvascular density. Here, KDR is linked to neoplasm.